Previous 10 | Next 10 |
home / stock / argnf / argnf news
Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. The Fund was down 7.1% (Institutional Shares) during the fourth quarter, compared to a gain of 2.2% for the Russell...
February 23 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webc...
January 27 , 202 3 Amsterdam , the Netherlands — argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (F...
Summary Argenx caught a strong bid in FY22 on the back of advancements in its Efgartigimod [Vyvgart] pipeline for Myasthenia Gravis. Demand began to fade rolling into the new year, with heavy outflows across the 3-months to-date. The company reported strong results in its Vyvgart se...
January 16 , 202 3 Amsterdam , the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an extraordinary general meeting of shareh...
Summary BAMCO’s 13F portfolio value decreased from $31.14B to $30.95B this quarter. Ron Baron decreased Rivian Automotive and Alphabet during the quarter. Their top five positions are at ~31% of the overall portfolio. This article is part of a series that provides an on...
Reported $ 40 2 million in preliminary * full-year 2022 global net VYVGART sales ADHERE topline results now expected in second quarter of 2023 ; Stage B enrollment has surpassed projected target of 130 patients Registra...
Summary Immunovant is developing a similar drug to argenx, but at 10% of argenx’s valuation, offering a good option value and a hedge against owning argenx. Immunovant has a new generation anti-FcRn IMVT-1402, and recent pre-clinical data showed that it does not impact albumin le...
Summary BMEZ’s portfolio has a combination of unknown small-cap "next generation" healthcare holdings and some familiar names in the field of biotechnology. Lack of diversification makes BMEZ susceptible to sector-specific risk. It also has a relatively high expense ratio despite...
Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...
News, Short Squeeze, Breakout and More Instantly...
July 18, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, Ju...
First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study July 16, 2024 6:30am CET Amsterdam, the Netherlands— ...
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional improvements with VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) , w...